Goldman Sachs
And Goldman Sachs this morning, on IMCL earnings:
"IMCL (OP/N): 1st take: Beat EPS on strong Erbitux and tax benefit
Imclone (OP/N) reported EPS of $2.51 vs. our est of $1.10 and consensus of $1.00. The upside reflects strong Erbitux sales, lower expenses, and a tax benefit of $1.08/sh. Domestic Erbitux sales were $138MM, $8MM better than our forecast and $7MM higher than consensus. Management indicated that there was no wholesaler stocking. Our estimates are under review."
Lawd! I love it.
And Goldman Sachs this morning, on IMCL earnings:
"IMCL (OP/N): 1st take: Beat EPS on strong Erbitux and tax benefit
Imclone (OP/N) reported EPS of $2.51 vs. our est of $1.10 and consensus of $1.00. The upside reflects strong Erbitux sales, lower expenses, and a tax benefit of $1.08/sh. Domestic Erbitux sales were $138MM, $8MM better than our forecast and $7MM higher than consensus. Management indicated that there was no wholesaler stocking. Our estimates are under review."
Lawd! I love it.
Comment